Evidence map›Paper›PMID 34325969›Full record

ArticleThe International journal on drug policy2021

A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment.

A Seaman, C A King, T Kaser, A Geduldig, W Ronan, R Cook, B Chan, X A Levander, K C Priest, P T Korthuis

Open access · greenAbstract read
In one paragraph

Article in The International journal on drug policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

A SeamanDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, United States; Hepatitis C Elimination Program, Central City Concern, Portland, Oregon, United States. Electronic address: seaman@ohsu.edu.
C A KingDept. of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, Oregon, United States.
T KaserHepatitis C Elimination Program, Central City Concern, Portland, Oregon, United States.
A GeduldigHepatitis C Elimination Program, Central City Concern, Portland, Oregon, United States.
W RonanHepatitis C Elimination Program, Central City Concern, Portland, Oregon, United States.
R CookDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, United States.
B ChanDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, United States; Hepatitis C Elimination Program, Central City Concern, Portland, Oregon, United States.
X A LevanderDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, United States.
K C PriestSchool of Medicine, MD/PhD Program, Oregon Health & Science University, Portland, Oregon, United States.
P T KorthuisDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, United States.
Oregon Health & Science University · USCentral City Concern · US

Funding

Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Oregon Clinical and Translational Research Institute TL1 ProgramTL1TR002371 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ALLISON Deborah FRYER, JESSINA C MCGREGOR · 2017 to 2026
$6.2M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
Variation in the Use of Opioid Agonist Treatment in HospitalsF30DA044700 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PRIEST, KELSEY CAROLINE · 2017 to 2020
$186k
Modeling the impact of hospital-based addiction consult services on post-discharge mortalityF30DA052972 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KING, CAROLINE · 2021 to 2021
$36k
NCATS NIH HHS TL1 TR002371NIDA NIH HHS F30 DA044700NIDA NIH HHS F30 DA052972NIDA NIH HHS U10 DA015815NIDA NIH HHS UG1 DA015815NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

backgroundReaching World Health Organization hepatitis C (HCV) elimination targets requires diagnosis and treatment of people who use drugs (PWUD) with direct acting antivirals (DAAs). PWUD experience challenges engaging in HCV treatment, including needing multiple provider and laboratory appointments. Women, minoritized racial communities, and homeless individuals are less likely to complete treatment.

methodsWe implemented a streamlined opt-out HCV screening and linkage-to-care program in two healthcare for the homeless clinics and a medically supported withdrawal center. Front-line staff initiated a single-order reflex laboratory bundle combining screening, confirmation, and pre-treatment laboratory evaluation from a single blood draw. Multinomial logistic regression models identified characteristics influencing movement through each stage of the HCV treatment cascade. Multiple logistic regression models identified patient characteristics associated with HCV care cascade progression and Cox proportional hazards models assessed time to initiation of DAAs.

resultsOf 11,035 clients engaged in services between May 2017 and March 2020, 3,607 (32.7%) were screened. Of those screened, 1,020 (28.3%) were HCV PCR positive. Of those with detectable RNA, 712 (69.8%) initiated treatment and 670 (94.1%) completed treatment. Of those initiating treatment, 407 (57.2%) achieved SVR12. There were eight treatment failures and six reinfections. In the unadjusted model, the bundle intervention was associated with increased care cascade progression, and in the survival analysis, decreased time to initiation; these differences were attenuated in the adjusted model. Women were less likely to complete treatment and SVR12 labs than men. Homelessness increased likelihood of screening and diagnosis but was negatively associated with completing SVR12 labs. Presence of opioid and stimulant use disorder diagnoses predicted increased care cascade progression.

conclusionsThe laboratory bundle and referral pathways improved treatment initiation, time to initiation, and movement across the cascade. Despite overall population improvements, women and homeless individuals experienced important gaps across the HCV care cascade.

Indexed as

Hepatitis CHepatitis C, ChronicIll-Housed PersonsAlgorithmsAntiviral AgentsDelivery of Health CareFemaleHepacivirusHumansLaboratoriesMaleAntiviral AgentsGenderHCV EliminationHepatitis CPeople experiencing homelessnessPeople Who Inject DrugsRace

Identifiers

PMID34325969
PMCPMC8720290
OpenAlexW3185847923

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.